Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- RDHL
- Price
- 1.33
- Stock movement up
- +0.03 (2.56%)
- Company name
- Redhill Biopharma Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 4.00M
- Ent value
- 23.92M
- Price/Sales
- 0.15
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 0.70
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -85.14%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2025-12-04
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
RDHL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 0.70 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 0.04 |
| EV to EBITDA | 0.23 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.15 |
| Price to Book | - |
| EV to Sales | 0.87 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.33M |
| EPS (TTM) | -3.73 |
| FCF per share (TTM) | -3.67 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 6.81M |
| Gross profit (TTM) | 4.31M |
| Operating income (TTM) | -7.46M |
| Net income (TTM) | -6.72M |
| EPS (TTM) | -3.73 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 63.30% |
| Operating margin (TTM) | -109.48% |
| Profit margin (TTM) | -98.66% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.87M |
| Net receivables | 6.36M |
| Total current assets | 12.55M |
| Goodwill | 0.00 |
| Intangible assets | 5.53M |
| Property, plant and equipment | 289.00K |
| Total assets | 18.38M |
| Accounts payable | 835.00K |
| Short/Current long term debt | 214.00K |
| Total current liabilities | 22.29M |
| Total liabilities | 22.79M |
| Shareholder's equity | -4.41M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -6.61M |
| Capital expenditures (TTM) | 8.00K |
| Free cash flow (TTM) | -6.62M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -36.59% |
| Return on Invested Capital | 160.15% |
| Cash Return on Invested Capital | 157.57% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.19 |
| Daily high | 1.20 |
| Daily low | 1.16 |
| Daily Volume | 40K |
| All-time high | 12368.75 |
| 1y analyst estimate | 19000.00 |
| Beta | 4.82 |
| EPS (TTM) | -3.73 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 12 Mar 2026 |
Downside potential
Loading...
Downside potential data
| RDHL | S&P500 | |
| Current price drop from All-time high | -99.99% | -0.89% |
| Highest price drop | -99.99% | -19.00% |
| Date of highest drop | 11 Nov 2025 | 8 Apr 2025 |
| Avg drop from high | -99.97% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 290 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
4.00M
Marketcap category
Small-cap
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Employees
35
Website
Investor relations
-
SEC filings
CEO
Dror Ben-Asher
Country
USA
City
Tel Aviv
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page